For our next session of Journal Club we welcome guest host Dr Daniel Casey.
Daniel has chosen to review:
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D. et al. (June 26 2021) “CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.” The New England Journal of Medicine. DOI: 10.1056/NEJMoa2107454
Dr Daniel Casey is a pharmaceutical physician currently working as Country Medical Lead for Celltrion Healthcare UK.
He is a Member of the Royal College of Psychiatrists and a Member of the Royal College of Physicians of London. He is currently an ST3 in the Pharmaceutical Medicine Specialty Training programme.
Dr Daniel Casey